15-69% of patients
face cancer recurrence [1] - [6]
which increases mortality by 2-18x [7] - [9].
Most of these patients have detectable minimal residual disease (MRD) within 18 months after surgery [10] - [12].
LucenceMONITOR is a minimal residual disease (MRD) test that screens for the recurrence of 6 cancers: breast, colorectal, lung, liver, pancreatic, and biliary tract cancer.
The test detects circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from cancer cells to track tumor-specific mutations.
LucenceMONITOR is recommended
-
4-6 weeks after surgery and repeated at 3 month intervals
Available internationally outside the USA.
LucenceMONITOR MRD program
Step 1: Eligibility
1 x LucenceMONITOR TissueBASELINE
Tissue and blood sample required
Patient must have tumor-specific mutation included in the gene list.
If eligible, blood sample is used for initial LucenceMONITOR LiquidMRD test
Step 2: Monitoring
4 x LucenceMONITOR LiquidMRD
Blood samples required
To be used within 12 months of
LucenceMONITOR TissueBASELINE
Specifications
LucenceMONITOR TissueBASELINE
>99%
Sensitivity
>99%
Specificity
0.9%VAF
DNA LOD
10 copies
RNA Fusion LOD
LucenceMONITOR LiquidMRD
>96%
Sensitivity
>95%
Specificity
0.1%VAF
DNA LOD
10 copies
RNA Fusion LOD
Downloads
References:
-
Nors, J. et al. JAMA Oncol. 2024; 10(1): 54-62.
-
Lyngholm, C. et al. Acta Oncol. 2016; 55(8): 983-992.
-
Karacz, C. et al. Clin. Lung Cancer. 2019; 21(2): 127-135.e3.
-
Kim, et al. Clin. Mol. Hepatol. 2020; 26(4): 516-528.
-
Murakawa, et al. World J. Surg. Oncol. 2023; 21(263).
-
Komaya, et al. Surgery 2018; 163(4): 732-738.
-
Balboa-Barreiro, V. et al. Dig. Liver Dis. 2024; 56(7): 1229-1236.
-
Dent, R. et al. Curr. Oncol. 2014; 21(3): e418-425.
-
Consonni, D. et al. J. Natl. Cancer Inst. 2015; 107(6): djv059.
-
Frydendahl, A. et al. EJC 2024; 211: 114314.
-
Zhang, J-T. et al. Cancer Discov. 2022; 12(7): 1690-1701.
-
Zhu, L. et al. Front. Genet. 2023; 14: 1172108.